The purpose of this review is to compare the clinical effectiveness and cost-effectiveness of imiquimod (IMQ) to other treatment modalities for the treatment of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). This report is the first in the series of three reports on IMQ. The following two reports will be on actinic keratosis and genital warts.
Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.